Andrew Longcore, identified as the corporate attorney for BidForMyMeds, demanded a retraction of a review published earlier this week. Longcore sent an email on January 7, 2014, claiming the review contained "false and misleading information" and threatened legal action if the article was not removed. The original review questioned BidForMyMeds' management, its affiliation with BidRx, and its business model.
The review noted that BidForMyMeds presented BidRx's executive management as its own. It also pointed to a lack of disclosure regarding who actually ran BidForMyMeds. Concerns were raised about the $17-a-month chain recruitment scheme.
Longcore's email stated BidForMyMeds is a "legitimate representative of BidRx, LLC." He said the company sells memberships allowing access to the BidRx system for purchasing prescription medication. Longcore asserted that BidForMyMeds allows potential savings to be seen before purchase, similar to a "free membership" from BidRx itself. He claimed all individuals must purchase a BidRx membership to place an order, even if they can view potential savings for free.
BidForMyMeds also offers individuals the chance to become distributors, providing materials and support for this business opportunity alongside their BidRx system access. Referral Partners earn compensation for membership sales. They can also build their own organization of Referral Partners and receive income from memberships sold by those beneath them.
Longcore called the claims of "no product" and "pyramid scheme" "uninformed analysis." He stated the review's author had not spoken to BidForMyMeds or BidRx, indicating negligence and a lack of knowledge. Longcore warned that such communications harm both BidForMyMeds and BidRx's reputation, causing "irreparable" damage. He concluded by requesting an immediate retraction. "Failure to do so will force Bid For My Meds to seek outside counsel to protect our rights to the fullest," Longcore wrote.
A response dated January 8, 2014, was sent to Longcore. It asked for clarification on BidForMyMeds' claim of being a "legitimate representative" of BidRx. The response questioned the existence of a contractual corporate relationship or direct affiliation between the two companies. It also asked if Ralph Kalies and Tom Kellenberger owned and operated BidForMyMeds. If not, the response questioned why their information appeared on BidForMyMeds' "About Us" page. It also asked who ran BidForMyMeds and why this information was absent from the website.
The response challenged Longcore's statement that "we sell memberships to the end user that allows them to access the BidRx system." This, the response noted, confirmed BidForMyMeds sells no retail products or services of its own. It suggested BidForMyMeds charges fees for access to a third-party system, which then offers discounts on third-party products. The response also cited BidRx's website, which states: "Any charge for participation is included in the cost of your prescription and collected by the pharmacy." This contradicts BidForMyMeds' flat-rate monthly fee, as BidRx's fees are based on the purchase of goods, not a subscription. The response also questioned if any money charged by BidForMyMeds is paid to BidRx for membership.